“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Laboratorios Grin, Lupin’s subsidiary in Mexico, remains one of the key players in the Ophthalmic segment and continues to deliver steady growth. The market witnessed robust growth of 8% in FY2020 albeit affected by currency devaluation due to macroeconomic headwinds.
Laboratorios Grin’s portfolio consists of 50 ophthalmic products and 10 primary care products. We intend to now leverage our global product pipeline and grow in areas beyond the ophthalmic segment by launching products in the respiratory, pain management and CNS segments.